A dispersant-free monodisperse nano-titanium dioxide acidic aqueous solution, its PEG-modified complex, its preparation method and application

By using an acidic aqueous solution of anatase-type nano-titanium dioxide without dispersants and covalent modification with PEG, the problems of aggregation and biocompatibility of nano-titanium dioxide in liquid systems were solved, achieving stable dispersion and efficient catalysis, which is suitable for medical materials and targeted delivery.

CN123105708APending Publication Date: 2026-11-17CHINA TOBACCO KANGKE (BEIJING) TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611374151.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-07
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing nano-titanium dioxide is prone to agglomeration in liquid systems, and its reliance on external dispersants poses a risk of biotoxicity. It also exhibits poor storage stability, and its PEG modification is not robust enough to achieve efficient monodispersion and biocompatibility.

Method used

A dispersant-free, acidic aqueous solution of anatase-type nano-titanium dioxide was used. Through electrostatic repulsion under extreme acidic conditions and PEG covalent modification, combined with an aqueous synthesis route, thermodynamically stable monodispersity and biocompatibility of nanoparticles were achieved.

Benefits of technology

It achieves long-term stable dispersion of nanoparticles in the liquid phase, has good biocompatibility, maintains catalytic activity, is suitable for medical materials and has targeted delivery function, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123105708A_ABST
    Figure CN123105708A_ABST
Patent Text Reader

Abstract

This invention discloses a dispersant-free monodisperse nano-titanium dioxide acidic aqueous solution, its polyethylene glycol (PEG) modified composite, its preparation method, and its applications. The solution comprises anatase nanoparticles and water, contains no added surfactants or dispersants, has a pH of 1.0-1.6, an average particle size of 2-20 nm, and can be stably stored for more than 24 months under sealed conditions, with a PDI change ≤0.20, preferably ≤0.08, and more preferably ≤0.05 after storage. PEG is covalently grafted to the surface using a silane coupling agent in a weakly acidic aqueous phase, forming a PEG-modified composite with excellent biocompatibility. The material of this invention can serve as a platform-type raw material and is widely applicable in biomedical fields such as medical dressings, drug carriers, medical coatings, and sonodynamic therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of nanobiomaterials, and particularly to a dispersant-free monodisperse nano-titanium dioxide acidic aqueous solution, its PEG-modified complex, preparation method, and application. Background Technology

[0002] Nano-titanium dioxide, with its excellent photocatalytic activity, high specific surface area, and chemical inertness, has shown great application potential in the biomedical field, particularly in antibacterial dressings, drug delivery, and sonodynamic therapy. However, existing technologies consistently face two major technical bottlenecks in achieving clinical translation.

[0003] First, nanoparticles are highly susceptible to irreversible aggregation in liquid systems. To maintain their dispersion, current mainstream processes generally rely on large amounts of surfactants or polymeric dispersants (such as polyvinylpyrrolidone, sodium citrate, etc.). These additives not only pose potential biotoxicity risks, easily triggering inflammatory responses in the body, but also mask the active sites on the nanoparticle surface, leading to catalyst deactivation. Furthermore, such dispersion systems exhibit poor stability during long-term storage; the dispersant is prone to desorption or degradation, resulting in particle sedimentation or flocculation, failing to meet the 24-month shelf-life requirements of medical products.

[0004] Secondly, existing methods for surface modification of polyethylene glycol (PEG) to improve biocompatibility have significant drawbacks. Currently, most methods employ physical adsorption, but the PEG chains have weak binding forces to the particles, making them prone to detachment in physiological environments and leading to opsonin uptake. Alternatively, organic phase synthesis routes are used, requiring toxic solvents such as toluene and xylene, resulting in difficult subsequent purification and solvent residues that fail to meet medical device-grade cleanliness standards. Furthermore, current technologies cannot achieve efficient aqueous covalent grafting while ensuring particle monodispersity, often resulting in trade-offs and a high polydispersity index (PDI) of the final product, making it unsuitable as a uniform platform-type raw material.

[0005] Therefore, it is necessary to develop a novel nano-titanium dioxide raw material that is completely independent of added dispersants, can achieve thermodynamically stable monodispersion in pure water systems, and can be firmly modified with PEG through a green aqueous phase process, in order to solve the problems of low biosafety, poor storage stability and complex processes of existing technologies. Summary of the Invention

[0006] In view of this, the present invention provides a dispersant-free monodisperse nano-titanium dioxide acidic aqueous solution, its PEG-modified complex, preparation method and application, to solve or alleviate one of the technical problems existing in the prior art, and at least provide a beneficial alternative.

[0007] The technical solution of this invention is implemented as follows: a monodisperse nano-titanium dioxide acidic aqueous solution without dispersant, the solution containing anatase nano-titanium dioxide particles and water, without added surfactants and / or dispersants; pH value of 1.0–1.6; average particle size of 2–20 nm; The absolute value of the Zeta potential of the anatase nano-titanium dioxide particles under pH 1.0-1.6 conditions is ≥35mV, and the Zeta potential originates from the electrostatic repulsion generated by the strong protonation of the particle surface. Furthermore, the absolute value of the Zeta potential of the nano-titanium dioxide particles under pH 1.0-1.6 conditions is ≥35mV, preferably +38mV to +55mV; The absolute value of the Zeta potential is obtained through the protonation of the particle surface in an extremely acidic environment. The protonation results in the particle surface having a uniformly distributed positive charge of the same kind, thereby forming a strong electrostatic repulsion between the particles. This electrostatic repulsion, in conjunction with steric hindrance, enables the particles to maintain a thermodynamically stable monodisperse state in the liquid phase. The solution can be stored stably for at least 24 months under sealed and light-protected conditions, and the PDI change after storage is ≤0.20, preferably ≤0.08, and more preferably ≤0.05.

[0008] Furthermore, the surface of the nano-titanium dioxide particles is at least partially covalently modified by molecules containing polyethylene glycol (PEG) chains via silane coupling groups; The silane coupling group is selected from at least one of 3-aminopropyltriethoxysilane, 3-glycidoxypropyltrimethoxysilane, vinyltrimethoxysilane, and silane coupling agents containing polyethylene glycol chains. The PEG chain molecular weight of the silane coupling agent containing polyethylene glycol chains is 200–20000 Da, preferably 1000–5000 Da. The PEG chains are distributed in a mushroom-like pattern on the particle surface, rather than being completely coated, thus imparting biocompatibility to the particles while preserving their integrity. High catalytic activity of the {101} crystal plane on the particle surface.

[0009] Furthermore, the free end of the PEG-containing molecule further comprises at least one active functional group selected from carboxyl, amino, and thiol groups; The active functional group is located at the free end of the PEG chain and is used for further chemical coupling reactions; When the active functional group is a carboxyl group, it can be activated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide and then coupled with the targeting ligand. When the active functional group is amino, it can be coupled with aldehyde-containing molecules through glutaraldehyde crosslinking; When the active functional group is a thiol group, it can be coupled with molecules containing double bonds via a maleimide reaction; The PEG-containing molecules are covalently grafted onto the surface of the nano-titanium dioxide particles; PEG modification must be covalent grafting. Possible covalent grafting routes include: condensing a silane coupling agent containing a PEG chain with Ti-OH on the TiO2 surface in an aqueous phase to form a -Ti-O-Si- bond; or first amening the TiO2 surface and then coupling it with mPEG-COOH via an amide bond. Simply physically adsorbed PEG is easily detached in physiological environments, making it difficult to stably meet the biocompatibility and long-term storage requirements of medical materials. Besides the above-mentioned covalent grafting routes, other grafting methods in the art that can form stable covalent bonds between PEG and the TiO2 surface should also be considered equivalent to the present invention.

[0010] Furthermore, a targeting ligand or imaging probe is coupled to the active functional group. The targeting ligand is covalently coupled to the active functional group at the free end of the PEG chain, enabling the nano-titanium dioxide particles to specifically recognize and bind to the corresponding receptors on the surface of target cells, thereby achieving targeted delivery. The targeting ligand is selected from at least one of folic acid, transferrin, hyaluronic acid, cRGD peptide, antibody, and aptamer; the imaging probe is selected from at least one of Gd-DOTA, indocyanine green, fluorescein, quantum dots, and rare earth upconversion nanoparticles.

[0011] Furthermore, in film-forming applications, the solution has a film-forming time of ≤2 seconds, a film-forming bonding strength of ≥10MPa, and a free nanoparticle release rate of less than 0.01% (w / w) after film formation.

[0012] The concentration of the nano-titanium dioxide particles is 0.1%-2.0% (w / w), preferably 0.5%-1.5% (w / w). The solution is stored stably at 5-35°C under sealed and light-protected conditions for at least 24 months, and the PDI change after storage is ≤0.20, preferably ≤0.08, and more preferably ≤0.05.

[0013] The pH value of the solution is obtained by adjusting an acidic medium, which is a dilute solution of at least one of nitric acid and sulfuric acid, or a hydrogen-form strong acid cation exchange resin. The solution has natural antibacterial properties under extremely acidic conditions, requiring no additional preservatives.

[0014] Furthermore, the following steps are included: (a) Provide an initial dispersion system of anatase nano-titanium dioxide particles in pure water with a pH of 3.0–6.0, free of added surfactants and / or dispersants; (b) A silane coupling agent containing PEG chains is added to the dispersion system obtained in step (a), and the reaction is carried out in a pure aqueous phase at 20–60 °C for 2–12 hours to covalently graft the PEG chains onto the surface of the nano-titanium dioxide particles; the reaction is carried out under light-protected conditions. (c) Purify the reaction product by removing unreacted PEG derivatives by at least one of centrifugation, dialysis, ultrafiltration or ceramic membrane perfiltration; (d) The dispersion system obtained in step (c) is brought into contact with an acidic medium to adjust the pH value to 1.0–1.6; the pH adjustment process is controlled by online pH monitoring to determine the endpoint of the pH adjustment. The acidic medium is at least one of nitric acid aqueous solution, sulfuric acid aqueous solution, or hydrogen-form strong acid cation exchange resin.

[0015] Step (d) involves rapidly injecting the pre-wetted slurry into an acidic receiving solution with a pH of 1.0–1.6, so that the particles are in an acidic environment throughout the process to avoid crossing the isoelectric point; The PEG-containing molecule is a PEG-containing silane coupling agent, or mPEG-COOH grafted with amide bonds after amination pretreatment.

[0016] Furthermore, the acidic medium mentioned in step (d) is an acidic aqueous solution and / or an ion exchange resin; The acidic aqueous solution is an aqueous solution of nitric acid or sulfuric acid with a concentration of 0.01-1.0 mol / L; The ion exchange resin is a hydrogen-form strong acid cation exchange resin. When the resin comes into contact with the dispersion, it is stirred slowly at a speed of 50-200 rpm for a contact time of 30-120 minutes. The pH adjustment process is controlled by online pH monitoring, and the resin is separated by filtration or sieving after the target pH value is reached. The choice of the acidic medium ensures that no additional metal ions or organic residues are introduced into the final solution.

[0017] Furthermore, the medical dressing is used for wound repair and antibacterial treatment; The drug carrier is used to load and deliver hydrophobic or hydrophilic drug molecules; The implant coating is used to impart antibacterial and biocompatible properties to the surface of the medical device; The bioimaging agent is used for fluorescence imaging or ultrasound imaging; The sonodynamic therapeutic agent is used to generate reactive oxygen species under ultrasonic excitation to kill diseased cells.

[0018] Furthermore, and a carrier that is acceptable in medical device science; The carrier is selected from at least one of nonwoven fabric, hydrocolloid, alginate, chitosan membrane, and hyaluronic acid gel; The content of nano-titanium dioxide in the medical dressing is 0.01%-5.0% (w / w); The medical dressing has antibacterial, healing-promoting, and biocompatible properties, and is suitable for covering and repairing burns, trauma, and chronic ulcers.

[0019] The PEG modification reaction was carried out in a pure aqueous phase without the use of organic solvents. The reaction was conducted with slow stirring under light-protected conditions.

[0020] The purification step employs at least one of centrifugation, dialysis, ultrafiltration, or ceramic membrane perfiltration to remove unreacted PEG derivatives.

[0021] Acidity adjustment can be achieved using a one-step pre-wetting-acidity adjustment method, in which the purified dispersion is rapidly injected into an acidic receiving solution with a pH of 1.0–1.6, and the endpoint of acidity adjustment is controlled by online pH monitoring.

[0022] The embodiments of the present invention have the following advantages due to the adoption of the above technical solutions: First, the solution described in this invention consists only of anatase nano-titanium dioxide particles and water, completely eliminating any added surfactants or dispersants. Combined with an extremely acidic environment of pH 1.0-1.6, the system itself possesses natural antibacterial capabilities, eliminating the risk of biotoxicity caused by external impurities at the source, and fully meeting the cleanliness requirements of medical-grade raw materials.

[0023] Secondly, this invention utilizes the electrostatic repulsion effect (Zeta potential ≥35mV absolute value) generated by strong protonation on the particle surface under extremely acidic conditions, combined with the steric hindrance effect provided by PEG modification, to achieve thermodynamically stable monodispersity of nanoparticles. Tests show that the solution can be stably stored for at least 24 months under sealed, light-protected conditions at 5-35℃, with a PDI change ≤0.05 after storage, solving the industry problem of easy aggregation of nanomaterials during long-term storage.

[0024] Third, this invention employs a silane coupling agent to directly covalently graft PEG onto a weakly acidic aqueous phase. Surface. The PEG layer, distributed in a "mushroom-like" pattern, not only provides excellent spatial stability but also greatly enhances the material's biocompatibility. ISO 10993-5 cytotoxicity testing verified that L929 cells achieved a survival rate of 97% in the extract, effectively reducing the risk of the material being cleared by the immune system in vivo.

[0025] Fourth, unlike the traditional strategy of fully encapsulating PEG, the modification method of this invention ensures that the PEG chains are not densely covered, but rather retain their integrity. The particle surface features highly active crystalline facets such as {101}. This allows the material to maintain excellent biosafety while retaining highly efficient acoustic-dynamic response performance; when used as a sonosensitive agent, it can inhibit tumor growth by up to 90%.

[0026] Fifth, this invention employs an aqueous synthesis route throughout, avoiding the use of organic solvents, and the reaction conditions are mild (20-60℃). The purification process is simple (requiring only centrifugation or ion exchange resin treatment). This method is green, environmentally friendly, and low-cost, making it highly suitable for large-scale industrial production and possessing extremely high industrial transformation value.

[0027] The above overview is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features of the invention will become readily apparent from the accompanying drawings and the following detailed description. Attached Figure Description

[0028] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0029] Figure 1 This is a flowchart illustrating the preparation process of the PEG-modified, dispersant-free acidic solution of the present invention.

[0030] Figure 2 This is a flowchart illustrating the construction process of the targeted functionalized acoustic sensor platform of the present invention.

[0031] Figure 3 This is a flowchart illustrating the implementation of the in vivo sonodynamic tumor treatment method of the present invention. Detailed Implementation

[0032] In the following description, only certain exemplary embodiments are briefly described. As those skilled in the art will recognize, the described embodiments can be modified in various ways without departing from the spirit or scope of the invention. Therefore, the drawings and description are considered to be exemplary in nature and not restrictive.

[0033] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings.

[0034] Example 1: Preparation of PEG-modified dispersant-free acidic solution

[0035] This embodiment details the complete preparation process of a dispersant-free monodisperse nano-titanium dioxide acidic aqueous solution, including four stages: initial dispersion, PEG covalent grafting, purification, and acid stabilization.

[0036] The embodiments can employ traditional stepwise preparation processes, while also supporting a one-step pre-wetting-acidification process. The core principle of the pre-wetting-acidification one-step process is to rapidly inject fully pre-wetted titanium dioxide powder slurry into an acidic receiving system, ensuring the nano-titanium dioxide particles remain in an acidic environment throughout the process. This avoids the system's pH crossing the isoelectric point of titanium dioxide, fundamentally inhibiting particle agglomeration. Through precise process logic control, a well-dispersed and highly stable PEG-modified nano-titanium dioxide acidic aqueous solution can be obtained, with the finished product exhibiting consistent overall performance with traditional processes and enhanced batch-to-batch stability.

[0037] To verify the performance advantages of the dispersant-free PEG covalently modified system of this invention, a control group consisting of a conventional PVP physical dispersion system was simultaneously set up. The control group, except for using a traditional PVP dispersant instead of the PEG covalent modification process, maintained identical raw material specifications, powder dosage, dispersion, reaction, purification, and acidification process parameters to this embodiment: 1.0g of the same anatase nano-titanium dioxide powder was weighed, and 0.08g of PVP-K30 conventional dispersant (the industry's optimal addition ratio) was added. After ultrasonic dispersion, conventional stirring, centrifugal washing, and acidification, an acidic aqueous control solution of PVP-dispersed nano-titanium dioxide was prepared for subsequent horizontal comparison of various performance characteristics.

[0038] (1) Initial dispersion: 1.0g of commercially available anatase nanoparticles were dispersed. The powder (average particle size approximately 10 nm, anatase crystal purity ≥95%) was dispersed in 100 mL of deionized water. The resistivity of the deionized water was 18.2 MΩ·cm, ensuring the absence of any ionic impurities. The dispersion was performed under ice bath conditions using a probe-type ultrasonic processor at a power of 150 W for 15 minutes, employing a pulse mode (2 seconds on, 1 second off) to prevent localized overheating. After ultrasonic treatment, The particles form a translucent, homogeneous dispersion in pure water with a pH of approximately 4.6. At this point, the system contains no added surfactants and / or dispersants. The particles maintain temporary dispersion stability by relying on the weak protonation effect on their surface in weakly acidic water.

[0039] (2) Covalent grafting of PEG: Under slow stirring, 10 mL of an aqueous solution containing 0.1 g of Silane-PEG-COOH was added to the initial dispersion. The structure of Silane-PEG-COOH is as follows: one end is a silane coupling group (3-aminopropyltriethoxysilane), the middle is a polyethylene glycol segment (molecular weight 3400 Da, about 77 repeating units), and the other end is a carboxyl (-COOH) active functional group. The system was placed under suitable temperature conditions for a sufficient reaction time, retaining conventional optimized process parameters, controlling the core reaction temperature at 50℃ and the total reaction time at 6 h, while avoiding core confidential process parameters such as precise feeding rate and refined pH monitoring window, and completing the grafting reaction under light-proof conditions. During the reaction, the silane coupling group hydrolyzes in the weakly acidic aqueous phase to generate silanol groups (Si-OH), which then undergo a condensation reaction with the hydroxyl groups (Ti-OH) on the particle surface to form a stable Si-O-Ti covalent bond, thereby firmly grafting the PEG chain onto the particle surface. The reaction system remained uniformly dispersed throughout, with no significant aggregation. The light-protected conditions were implemented to prevent unnecessary side reactions caused by photocatalytic activity during the reaction process.

[0040] (3) Purification: After the PEG grafting reaction is completed, the reaction solution is purified by centrifugation. After centrifugation, the supernatant is discarded, the precipitate is resuspended in deionized water and centrifuged again. This washing process is repeated three times to remove unreacted Silane-PEG-COOH and hydrolysis byproducts.

[0041] (4) Acidification Stabilization: The purified PEG-modified dispersion is contacted with a hydrogen-form strong acidic cation exchange resin. There is no need to specify the exact type or dosage of the resin; acidification and impurity ion replacement are achieved solely through resin contact. Under slow stirring, the H+ on the resin... + Ions are gradually released into the solution, simultaneously exchanging and adsorbing other cations in the solution. After stirring for a certain period of time, the pH value of the solution is monitored, and stirring is stopped when the pH value reaches 1.30. Resin particles are removed by filtration (using a 200-mesh nylon sieve), and the filtrate is collected to obtain the monodisperse, PEG-modified, nano-titanium dioxide acidic aqueous solution without dispersant.

[0042] Product characterization results

[0043] The product obtained in Example 1 underwent comprehensive physicochemical characterization and biological evaluation, and the results are as follows: Particle size and dispersibility: Dynamic light scattering (DLS) measurements showed that the hydrated particle size of the composite particles was approximately 25 nm (original). With a particle size of approximately 10 nm and a PEG layer contributing approximately 15 nm of hydration layer thickness, the polydispersity index (PDI) of 0.04 indicates an extremely narrow particle size distribution and excellent monodispersity.

[0044] Under the same testing conditions, the hydrated particle size of the control group sample with PVP dispersant was 42 nm, and the polydispersity index (PDI) was 0.21, showing obvious slight particle agglomeration. Furthermore, after standing for 72 hours, the PVP system exhibited trace precipitation and increased particle size fluctuations. In contrast, the particle size and PDI value of the PEG covalently modified system without dispersant showed no significant changes, and its dispersion stability and batch uniformity were significantly superior to the traditional PVP physical dispersion system. The core reason is that PVP adheres to the particle surface solely through physical adsorption, resulting in weak binding force and easy desorption. In contrast, PEG is stably grafted through Si-O-Ti covalent bonds, without dispersant interference, leading to more durable system dispersion uniformity.

[0045] Zeta potential: The zeta potential was measured to be +42mV at pH 1.30, indicating that the particle surface carries a large number of positive charges and has strong electrostatic repulsion. This, along with the PDI data, confirms the excellent stability of the system.

[0046] Under the same pH conditions, the Zeta potential of the PVP dispersion control group was +28mV, and the surface charge density was much lower than that of the system of this invention. Traditional PVP dispersants form a coating layer on the particle surface, shielding part of the particle surface charge and reducing the electrostatic repulsion between particles. This is one of the core reasons why the PVP system is prone to aggregation and has poor stability, further highlighting the stability advantage of this process without dispersant covalent modification.

[0047] Infrared spectroscopy (FT-IR): at 1105 The presence of a distinct COC characteristic absorption peak, corresponding to the stretching vibration of the ether bond in the PEG chain, confirms that PEG has been successfully grafted onto the COC. Surface. Meanwhile at 1630 The observation of the C=O stretching vibration peak of the carboxyl group indicates that the carboxyl group at the end of the PEG chain is well preserved.

[0048] Thermogravimetric analysis (TGA): Under a nitrogen atmosphere, the temperature was increased from room temperature to 800℃ at a rate of 10℃ / min. The results showed that the PEG-modified particles exhibited a significant weight loss step in the 300-450℃ range, corresponding to the thermal decomposition of the PEG chains. The calculated PEG grafting rate was approximately 8.5% (mass fraction). This grafting rate indicates that the particle surface is covered with an appropriate amount of PEG chains, ensuring biocompatibility without excessively obscuring surface active sites.

[0049] Photocatalytic activity comparison: The photocatalytic degradation rate of methyl orange solution was used as the evaluation index. The photocatalytic activity of two groups of samples was tested under the same light conditions and the same sample dosage. The PEG-modified nano-titanium dioxide of this invention, without dispersant, achieved a methyl orange degradation rate of 92.3% after adsorption equilibrium in the dark and irradiated with ultraviolet light for 60 min. In contrast, the methyl orange degradation rate of the control group with PVP dispersant was only 70.5% under the same conditions.

[0050] Reasons for performance differences: Traditional PVP dispersants are organic polymer coating materials that physically cover the photocatalytic active sites on the surface of titanium dioxide particles, while hindering light penetration and interfacial mass transfer, thus significantly weakening photocatalytic performance. In contrast, this invention uses a dispersant-free covalent grafting process, with controllable PEG grafting amount and uniform and thin coating. It only optimizes dispersion performance, retaining the intrinsic photocatalytic activity of titanium dioxide to the greatest extent, and solving the technical pain point of "improved dispersibility but decreased activity" in conventional dispersant systems.

[0051] Cytotoxicity: In vitro cytotoxicity tests were conducted according to ISO 10993-5. L929 mouse fibroblasts were seeded into 96-well plates, and different concentrations of sample extracts were added (extraction conditions: 37℃, 24h). After culturing for 48h, cell viability was determined by the MTT assay. The results showed that within the tested concentration range, the viability of L929 cells in the extract was 97%, far exceeding the 95% threshold required for biocompatibility in medical devices, confirming the excellent biocompatibility of the material.

[0052] Under the same biocompatibility testing conditions, the survival rate of L929 cells in the PVP dispersant control group was only 91.2%, lower than the industry's 95% pass threshold, indicating slight cytotoxicity. The reason for this is that PVP is a physical adsorption dispersant, which is prone to slow desorption and free precipitation in aqueous solutions. Trace amounts of free PVP polymers can slightly inhibit cell proliferation. In contrast, the system of this invention contains no external dispersant, and PEG is firmly grafted via covalent bonds, preventing the precipitation of free organic impurities. Its biocompatibility is far superior to conventional PVP dispersion systems, making it suitable for demanding applications such as medical and biosensing applications.

[0053] Summary table of product characterization data in Example 1

[0054] Example 2: Construction of a Targeted Functional Platform

[0055] This embodiment describes, based on Example 1, the construction of a tumor-targeting ligand by utilizing the carboxyl functional group at the end of the PEG chain and coupling it with a folic acid targeting ligand via EDC / NHS activation. Detailed process of the PEG-FA complex. This complex can be used in tumor-targeted sonodynamic therapy research.

[0056] (1) Carboxyl activation: Take the PEG-modified material redispersed in step (3) of Example 1 Solution (containing 1.0g PEG-) The PEG-modified dispersion was prepared in 100 mL of deionized water. EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and NHS (N-hydroxysuccinimide) were added to the dispersion. The amount of EDC added was 10 mg / mL of dispersion, and the amount of NHS added was 15 mg / mL of dispersion. EDC and NHS were pre-dissolved separately in small amounts of deionized water and then added sequentially to the PEG-modified dispersion. The activation reaction was carried out at room temperature (25°C) with stirring in the dark for 30 minutes. During this process, EDC reacts with the carboxyl groups at the ends of the PEG chains to form an unstable acylisourea intermediate. The addition of NHS converts this intermediate into a more stable NHS ester, preparing for the subsequent coupling reaction with folic acid.

[0057] (2) Folic acid coupling: Folic acid (FA) solution was added to the activated dispersion. Folic acid was first dissolved in a small amount of 1 mol / L NaOH solution, and then diluted with MES buffer at pH 5.0 to a concentration of 2 mg / mL. The amount of folic acid solution added was 20 mL per 100 mL of dispersion (i.e., containing 40 mg of folic acid). The system was stirred and reacted at room temperature in the dark for 12 hours. During the reaction, the amino group on the folic acid molecule underwent amidation with the NHS ester at the end of the PEG chain to form a stable amide bond, thereby covalently coupling folic acid to the free end of the PEG chain. As a classic tumor-targeting ligand, folic acid can specifically recognize the overexpressed folic acid receptor on the surface of tumor cells, endowing nanoparticles with active targeting capabilities.

[0058] (3) Purification: After the reaction, the dispersion was transferred to a dialysis bag (molecular weight cutoff 3500 Da) and purified by dialysis in a large volume of deionized water for 24 hours, with the external dialysis solution replaced every 6 hours. The purpose of dialysis was to remove unreacted folic acid, EDC, NHS, and other small molecule impurities. After dialysis, the solution in the dialysis bag was collected, which is the folic acid-targeted solution. -PEG-FA complex solution. The absorbance of the complex at 280 nm and 360 nm was measured by UV-Vis spectrophotometer, and the coupling efficiency of folic acid was calculated. The results showed that the folic acid coupling rate was approximately 85%.

[0059] (4) Characterization and verification: The obtained The PEG-FA complex was characterized. DLS measurements showed a hydrated particle size of approximately 28 nm (slightly larger than the uncoupled folic acid size of 25 nm, attributed to the addition of folic acid molecules), PDI = 0.03, maintaining excellent monodispersity. The Zeta potential was measured at pH 1.30 as +38 mV, slightly lower than the uncoupled state (from +42 mV to +38 mV), which is attributed to a slight decrease in surface charge density due to the consumption of some carboxyl groups by folic acid. FT-IR spectra were obtained at 1605 nm. A new absorption peak appeared, corresponding to the C=C stretching vibration of the folic acid benzene ring, confirming successful folic acid coupling. Fluorescence microscopy showed that the complex could be effectively taken up by HeLa cells with high folic acid receptor expression, with an uptake efficiency approximately 5 times that of cells with low receptor expression, confirming the achievement of the targeting function.

[0060] Example 3: In vivo sonodynamic tumor therapy experiment

[0061] This example describes the preparation using Example 2. This document details the in vivo sonodynamic antitumor therapy experiment using the PEG-FA complex, including animal model establishment, drug administration regimen, ultrasound treatment, and efficacy evaluation. This embodiment fully demonstrates the practical application effects of the material of this invention in the field of tumor treatment.

[0062] (1) Animal model establishment: 6-8 week old BALB / c nude mice (female, weighing 18-22g) were selected, and HeLa human cervical cancer cell suspension (cell density of 5×10⁻⁶) was injected subcutaneously into the right axilla. 6 A solid tumor model was established by injecting tumor cells at a rate of 0.1 mL per mouse. Tumor volume was measured every two days using calipers (tumor volume = major axis × minor axis² / 2). When the tumor volume reached approximately 100-150 mm³ (usually 10-14 days after inoculation), the tumor-bearing mice were randomly divided into four groups of eight mice each: control group (saline only), ultrasound control group (saline + ultrasound), material control group (…). -PEG-FA + folic acid-free control + ultrasound), treatment group ( -PEG-FA+ultrasound).

[0063] (2) Administration regimen: The treatment group and the material control group were administered the drug via tail vein injection, with an injection volume of 200 μL / animal (containing Approximately 2 mg of PEG-FA complex (Equivalent). After injection, the nanoparticles are distributed throughout the body via blood circulation. Because folic acid receptors are highly expressed in HeLa tumor cells, The PEG-FA complex specifically accumulates in tumor tissue via folate-folate receptor-mediated endocytosis. Twenty-four hours post-injection, in vivo imaging monitoring of the nanoparticle distribution revealed significant fluorescence signals at the tumor site (from...). The intrinsic fluorescence of the sample was observed, while the signal in normal tissue was weaker, confirming the targeted enrichment effect.

[0064] (3) Ultrasound treatment: Twenty-four hours after injection, both the treatment group and the ultrasound control group underwent ultrasound irradiation. A low-intensity focused ultrasound device was used with the following parameters: frequency 1 MHz, sound intensity 1.0 W / cm², duty cycle 50%, and irradiation time 5 minutes. During ultrasound treatment, mice were fixed under anesthesia, ultrasound coupling agent was applied to the tumor site, and the ultrasound probe was aimed at the tumor area. Under ultrasound excitation, the tumor site was enriched with... Nanoparticles generate a large number of reactive oxygen species, including superoxide anions, hydroxyl radicals and singlet oxygen. These ROS cause severe oxidative damage to tumor cells, inducing apoptosis and necrosis.

[0065] (4) Evaluation of efficacy: After ultrasound treatment, tumor growth was monitored, and tumor volume was measured every two days for 21 days. Mouse weight changes were also monitored to assess systemic toxicity. After treatment, tumor tissue was collected for histological analysis (H&E staining and TUNEL apoptosis staining). Results showed that tumors in the control group and ultrasound control group continued to grow rapidly, increasing in volume by approximately 8-10 times within 21 days; tumor growth in the material control group (without folic acid targeting) was slightly inhibited (tumor inhibition rate approximately 20%), indicating a certain degree of passive enrichment (EPR effect); the treatment group ( Tumor growth was significantly inhibited by PEG-FA + ultrasound, with a tumor inhibition rate of 90%, and the tumor volume remained essentially unchanged during the observation period. H&E staining showed extensive necrosis and inflammatory cell infiltration in the tumor tissue of the treatment group; TUNEL staining showed a large number of apoptotic cells (apoptosis index of approximately 65%) in the tumor tissue of the treatment group, while only about 5% were observed in the control group. In terms of systemic toxicity assessment, the mice in the treatment group showed stable weight gain during the experiment, and liver and kidney function indicators (ALT, AST, BUN, Cr) were all within the normal range. No obvious pathological damage was observed in the H&E sections of the major organs (heart, liver, spleen, lung, kidney), indicating that the treatment regimen had no significant systemic toxicity.

[0066] (5) Long-term safety observation: After treatment, mice were observed for another 30 days. All mice in the treatment group survived (survival rate 100%), and there were no signs of tumor recurrence. Hematological indicators (red blood cell, white blood cell, and platelet counts) were all within the normal range. These results collectively indicate that the invention provides... The PEG-FA sonodynamic therapy platform has excellent anti-tumor effects and good biosafety, and has the potential for clinical application.

[0067] Example 3: Summary Table of Therapeutic Effect Data

[0068] Industrial applicability

[0069] The solution of this invention, as a clean, stable, and biocompatible platform-type nanomaterial, can be widely used in the preparation of high-end medical dressings, nanomedicine carriers, antibacterial coatings for implantable devices, and as a core sonosensitive agent in sonodynamic therapy. In medical dressings, this solution can be directly coated or impregnated onto carriers such as nonwoven fabrics and hydrocolloids for covering and repairing wounds such as burns, trauma, and chronic ulcers. Its naturally acidic environment and... The photocatalytic activity of PEG-modified PEG contributes to the excellent antibacterial properties of the dressing. Regarding drug carriers, PEG-modified PEG... The particles can serve as a nanoscale drug delivery platform, loading various hydrophobic or hydrophilic drug molecules onto their surface functional groups to achieve controlled release and targeted delivery. In implant coatings, this solution can form antibacterial and biocompatible coatings on medical device surfaces through dip coating, spraying, or electrochemical deposition, reducing the risk of post-implantation infection. In sonodynamic therapy, this material serves as a core sonosensitive agent, efficiently generating reactive oxygen species under ultrasonic excitation for tumor treatment.

[0070] The preparation process of this invention is green, safe, and easily scalable. The entire production process uses only water as a solvent, without involving organic solvents or generating harmful waste. Key steps (ultrasonic dispersion, silane coupling, centrifugal purification, and ion exchange acidification) are all mature industrial unit operations, which can be achieved through continuous or batch-scale production using standard equipment. Product quality is stable and controllable; key quality indicators (particle size, PDI, Zeta potential, and PEG grafting rate) can be strictly controlled through online monitoring and offline detection. Therefore, this invention has extremely high industrial transformation value and broad market prospects, and is expected to form a core technology with independent intellectual property rights in the field of biomedical materials.

[0071] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can easily conceive of various variations or substitutions within the technical scope disclosed in the present invention, and these should all be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A monodisperse nano-titanium dioxide acidic aqueous solution without a dispersant, characterized in that, The solution contains anatase nano-titanium dioxide particles and water, and contains no added surfactants and / or dispersants; the pH value is 1.0–1.6; the average particle size is 2–20 nm; The absolute value of the Zeta potential of the anatase nano-titanium dioxide particles under pH 1.0-1.6 conditions is ≥35mV, and the Zeta potential originates from the electrostatic repulsion caused by the strong protonation of the particle surface.

2. The solution according to claim 1, characterized in that, The absolute value of the Zeta potential of the nano-titanium dioxide particles under pH 1.0-1.6 conditions is ≥35mV, preferably +38mV to +55mV; The absolute value of the Zeta potential is obtained through the protonation of the particle surface in an extremely acidic environment. The protonation results in the particle surface having a uniformly distributed positive charge of the same kind, thereby forming a strong electrostatic repulsion between the particles. This electrostatic repulsion, in conjunction with steric hindrance, enables the particles to maintain a thermodynamically stable monodisperse state in the liquid phase. The solution can be stored stably for at least 24 months under sealed and light-protected conditions, and the PDI change after storage is ≤0.20, preferably ≤0.08, and more preferably ≤0.

05.

3. The solution according to claim 1, characterized in that, The surface of the nano-titanium dioxide particles is at least partially covalently modified by molecules containing polyethylene glycol (PEG) chains via silane coupling groups; The silane coupling group is selected from at least one of 3-aminopropyltriethoxysilane, 3-glycidoxypropyltrimethoxysilane, vinyltrimethoxysilane, and silane coupling agents containing polyethylene glycol chains. The PEG chain molecular weight of the silane coupling agent containing polyethylene glycol chains is 200–20000 Da, preferably 1000–5000 Da. The PEG chains are distributed in a mushroom-like pattern on the particle surface, rather than being completely coated, thus imparting biocompatibility to the particles while preserving their integrity. High catalytic activity of the {101} crystal plane on the particle surface.

4. The solution according to claim 3, characterized in that, The free end of the PEG-containing molecule further comprises at least one active functional group selected from carboxyl, amino, and thiol groups; The active functional group is located at the free end of the PEG chain and is used for further chemical coupling reactions; When the active functional group is a carboxyl group, it can be activated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide and then coupled with the targeting ligand. When the active functional group is amino, it can be coupled with aldehyde-containing molecules through glutaraldehyde crosslinking; When the active functional group is a thiol group, it can be coupled with molecules containing double bonds via a maleimide reaction; The PEG-containing molecules are covalently grafted onto the surface of the nano-titanium dioxide particles.

5. The solution according to claim 4, characterized in that, The active functional group is further coupled with a targeting ligand or imaging probe. The targeting ligand is covalently coupled to the active functional group at the free end of the PEG chain, so that the nano-titanium dioxide particles can specifically recognize and bind to the corresponding receptors on the surface of the target cells, thereby achieving the targeted delivery function. The targeting ligand is selected from at least one of folic acid, transferrin, hyaluronic acid, cRGD peptide, antibody, and aptamer; the imaging probe is selected from at least one of Gd-DOTA, indocyanine green, fluorescein, quantum dots, and rare earth upconversion nanoparticles.

6. The solution according to any one of claims 1 to 5, characterized in that, In film-forming applications, the solution has a film-forming time of ≤2 seconds, a film-forming bonding strength of ≥10MPa, and a free nanoparticle release rate of less than 0.01% (w / w) after film formation. The concentration of the nano-titanium dioxide particles is 0.1%-2.0% (w / w), preferably 0.5%-1.5% (w / w). The solution is stored stably at 5-35°C under sealed and light-protected conditions for at least 24 months, and the PDI change after storage is ≤0.20, preferably ≤0.08, and more preferably ≤0.

05. The pH value of the solution is obtained by adjusting an acidic medium, which is a dilute solution of at least one of nitric acid and sulfuric acid, or a hydrogen-form strong acid cation exchange resin. The solution has natural antibacterial properties under extremely acidic conditions, requiring no additional preservatives.

7. A method for preparing the solution according to any one of claims 1 to 6, characterized in that, Includes the following steps: (a) Provide an initial dispersion system of anatase nano-titanium dioxide particles in pure water with a pH of 3.0–6.0, free of added surfactants and / or dispersants; (b) A silane coupling agent containing PEG chains is added to the dispersion system obtained in step (a), and the reaction is carried out in a pure aqueous phase at 20–60 °C for 2–12 hours to covalently graft the PEG chains onto the surface of the nano-titanium dioxide particles; the reaction is carried out under light-protected conditions. (c) Purify the reaction product by removing unreacted PEG derivatives by at least one of centrifugation, dialysis, ultrafiltration or ceramic membrane perfiltration; (d) The dispersion system obtained in step (c) is brought into contact with an acidic medium to adjust the pH value to 1.0–1.6; the pH adjustment process is controlled by online pH monitoring to reach the endpoint. The acidic medium is at least one of nitric acid aqueous solution, sulfuric acid aqueous solution, or hydrogen-form strong acid cation exchange resin. Step (d) involves rapidly injecting the pre-wetted slurry into an acidic receiving solution with a pH of 1.0–1.6, so that the particles are in an acidic environment throughout the process to avoid crossing the isoelectric point.

8. The method according to claim 7, characterized in that, The acidic medium mentioned in step (d) is an acidic aqueous solution and / or an ion exchange resin; The acidic aqueous solution is an aqueous solution of nitric acid or sulfuric acid with a concentration of 0.01-1.0 mol / L; The ion exchange resin is a hydrogen-form strong acid cation exchange resin. When the resin comes into contact with the dispersion, it is stirred slowly at a speed of 50-200 rpm for a contact time of 30-120 minutes. The pH adjustment process is controlled by online pH monitoring, and the resin is separated by filtration or sieving after the target pH value is reached. The choice of the acidic medium ensures that no additional metal ions or organic residues are introduced into the final solution.

9. The use of the dispersant-free monodisperse nano-titanium dioxide acidic aqueous solution according to any one of claims 1 or 6 in the preparation of medical dressings, drug carriers, implant coatings, bioimaging agents, or sonodynamic therapy agents, characterized in that, in, The medical dressing is used for wound repair and antibacterial treatment; The drug carrier is used to load and deliver hydrophobic or hydrophilic drug molecules; The implant coating is used to impart antibacterial and biocompatible properties to the surface of the medical device; The bioimaging agent is used for fluorescence imaging or ultrasound imaging; The sonodynamic therapeutic agent is used to generate reactive oxygen species under ultrasonic excitation to kill diseased cells.

10. A medical dressing comprising a monodisperse nano-titanium dioxide acidic aqueous solution without dispersant as described in any one of claims 1 to 6, characterized in that, And a carrier that is acceptable in medical device science; The carrier is selected from at least one of nonwoven fabric, hydrocolloid, alginate, chitosan membrane, and hyaluronic acid gel; The content of nano-titanium dioxide in the medical dressing is 0.01%-5.0% (w / w); The medical dressing has antibacterial, healing-promoting, and biocompatible properties, and is suitable for covering and repairing burns, trauma, and chronic ulcers.